Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs Fox Corp Class B (FOX) Price & Performance

Adaptive Biotechnologies CorpTrade
Fox Corp Class BTrade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs Fox Corp Class B — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.05B), while Fox Corp Class B trades at $55.42 (market cap $25.05B). The key difference: Fox Corp Class B is far larger — about 6.2× Adaptive Biotechnologies Corp's market cap, and Fox Corp Class B pays a 1.03% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.

ADPTFOX
Market Cap
$4.05B$25.05B
Sector
HealthMedia
52-Week High
$25.45$67.76
52-Week Low
$12.15$44.39
Enterprise Value
$4.12B$28.41B
Dividend Yield
1.03%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.

Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.

Fox Corp Class B

FOX stock trades at $57.03, up 3.0% in 24 hours, reflecting strong momentum. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026 underscore robust performance, with revenue reaching $16.30 billion in 2025. Technical indicators signal bullish trends, supported by moving averages, while RSI levels suggest potential overbought conditions. The company maintains solid profitability with a net income margin of 9.84% and ROE of 14.29%, though valuation metrics like P/E of 14.84 appear reasonable relative to peers.

Outlook remains positive driven by ad demand and digital growth, including Tubi and FOX One initiatives. Risks include reliance on advertising cycles and competitive pressures. Analyst consensus leans neutral with 42.86% buy ratings, but recent news highlights operational strength. Investors should weigh earnings consistency against market volatility and sector headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About Fox Corp Class B

Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.

Read more on FOX